Excelestar Ventures

Founded in 2010, Excelestar Ventures is a global venture capital firm that selectively invests in mature businesses with proven intrinsic value. They focus on B2B companies operating in technology and medical devices sectors, providing operational support to drive growth and sustainable profits.

Ibrahim Al-Qamari

Principal

Emily Giudice

Principal

24 past transactions

Adona Medical

Series C in 2024
Adona Medical innovates interventional approaches for managing heart failure, a progressive condition affecting millions globally. Its platform aims to improve care by enabling personalized management of cardiac patients through advanced sensor and shunt technologies.

Brixton Biosciences

Series B in 2024
Brixton Biosciences is a clinical-stage life sciences company developing therapies for pain management. The company focuses on non-addictive, locally targeted treatments delivered via a drug-free injectable that produces reversible nerve inhibition, aiming to provide long-lasting relief. Its lead approach seeks to extend pain relief from a single injection to thirty to sixty days, reducing reliance on systemic medications and addressing unmet needs in both chronic and acute pain.

Instylla

Series C in 2023
Instylla is a medical equipment supplier specializing in the development of next-generation liquid embolics for interventional radiology. Based in Bedford, Massachusetts, the company focuses on creating innovative embolization products to enhance patient outcomes in areas such as peripheral hemostasis and interventional oncology.

Sealonix

Series A in 2023
Sealonix is a company dedicated to the development and commercialization of innovative hemostatic sealants utilizing proprietary biomaterials. It specializes in creating a sealant patch designed to achieve rapid hemostasis during surgical procedures, specifically targeting abdominopelvic and orthopedic operations. The PramStat patch is engineered to bioabsorb within one week of implantation, offering a timely solution for surgeons and enhancing patient safety and recovery.

Datacy

Seed Round in 2022
Datacy is a venture-backed company that specializes in providing a consumer insights data platform aimed at enhancing revenue growth for consumer packaged goods (CPG) in the digital commerce sector. The company empowers consumers by allowing them to control and monetize their personal data while offering businesses a comprehensive understanding of the factors influencing online shopping decisions. Datacy's platform features data collection, secure access, automated organization, and robust privacy measures, enabling clients to efficiently manage and analyze extensive online consumer behavior data. By connecting and interpreting billions of data points, Datacy reveals the intricate patterns and preferences that drive consumer choices, thereby offering valuable insights that facilitate strategic decision-making in digital marketing.

Adona Medical

Series B in 2022
Adona Medical innovates interventional approaches for managing heart failure, a progressive condition affecting millions globally. Its platform aims to improve care by enabling personalized management of cardiac patients through advanced sensor and shunt technologies.

Concerto Biosciences

Venture Round in 2022
Concerto Biosciences develops microbe-based products that rebuild microbial communities in and around humans and ecosystems. The company uses an ultra-high-throughput platform to experimentally measure millions of microbial interactions and map interaction networks, enabling the discovery of ensembles, which are specific combinations of microbes that work together to shepherd damaged microbial communities back to health. These ensembles have potential applications across medicine and agriculture, addressing global challenges in health, food, and industry. By focusing on microbial community engineering, Concerto aims to become a leading inventor of ensembles and to redefine how microbiomes are leveraged for health and environmental outcomes.

Chromatic 3D Materials

Venture Round in 2021
Chromatic 3D Materials specializes in developing advanced materials for additive manufacturing. They focus on creating durable elastomer materials for 3D printing, enabling the production of flexible and resilient parts suitable for finished manufactured goods.

RoadSync

Series B in 2021
Founded in 2015, RoadSync specializes in developing an online payment platform tailored for various industries within the logistics sector. Its platform enables users to provide instant receipts, view billing activities, and facilitate recurring transactions. Serving warehouses, repair services, drivers, and other logistics professionals, RoadSync aims to automate financial solutions and modernize commerce within the $800 billion logistics industry.

Brixton Biosciences

Venture Round in 2021
Brixton Biosciences is a clinical-stage life sciences company developing therapies for pain management. The company focuses on non-addictive, locally targeted treatments delivered via a drug-free injectable that produces reversible nerve inhibition, aiming to provide long-lasting relief. Its lead approach seeks to extend pain relief from a single injection to thirty to sixty days, reducing reliance on systemic medications and addressing unmet needs in both chronic and acute pain.

Instylla

Series B in 2020
Instylla is a medical equipment supplier specializing in the development of next-generation liquid embolics for interventional radiology. Based in Bedford, Massachusetts, the company focuses on creating innovative embolization products to enhance patient outcomes in areas such as peripheral hemostasis and interventional oncology.

Terecircuits

Venture Round in 2020
Terecircuits develops materials and processes to enable microassembly and mass transfer for displays and advanced electronics. The company offers advanced polymers, encapsulation materials, and liquid metal interconnects, along with photo-polymer mass transfer used in MicroLEDs for automotive and AR/VR applications. It also develops new materials and design language for systems-in-package manufacturing to support Internet of Things and health technology. Serving the display, electronics, and semiconductor industries, the company focuses on precision mass transfer, lightweight embedded sensors, and lower-power circuitry to enable faster, lower-cost device production. It is based in Mountain View, California.

Adona Medical

Series A in 2020
Adona Medical innovates interventional approaches for managing heart failure, a progressive condition affecting millions globally. Its platform aims to improve care by enabling personalized management of cardiac patients through advanced sensor and shunt technologies.

Kinnos

Series A in 2020
Kinnos Inc. is a biotechnology company based in Brooklyn, New York, that specializes in innovative color technology to enhance disinfection practices. Founded in 2014, the company manufactures Highlight, a patent-pending powdered additive that improves the visibility of disinfectants, thereby increasing user compliance and ensuring thorough cleaning. Highlight provides real-time color-change feedback, empowering individuals to disinfect surfaces with confidence. In addition to the Highlight additive, Kinnos offers Highlight Wipes, a dispensing machine for wipes, and Highlight Powder, a disinfectant additive. The company's mission is to transform how disinfectants are used, ultimately aiming to prevent disease outbreaks and promote public health through visible disinfection.

Kinnos

Venture Round in 2020
Kinnos Inc. is a biotechnology company based in Brooklyn, New York, that specializes in innovative color technology to enhance disinfection practices. Founded in 2014, the company manufactures Highlight, a patent-pending powdered additive that improves the visibility of disinfectants, thereby increasing user compliance and ensuring thorough cleaning. Highlight provides real-time color-change feedback, empowering individuals to disinfect surfaces with confidence. In addition to the Highlight additive, Kinnos offers Highlight Wipes, a dispensing machine for wipes, and Highlight Powder, a disinfectant additive. The company's mission is to transform how disinfectants are used, ultimately aiming to prevent disease outbreaks and promote public health through visible disinfection.

Conformal Medical

Series B in 2018
Conformal Medical, Inc., established in 2016 and based in Nashua, New Hampshire, specializes in developing medical devices aimed at preventing stroke in patients with atrial fibrillation (AFib). The company's primary product is the CLAAS Technology, a solution designed to seal the left atrial appendage (LAA) in AFib patients. This technology forms part of their conformal left atrial appendage closure (LAAC) system.

Lantos

Venture Round in 2018
Lantos Technologies, Inc., established in 2009 and headquartered in Derry, New Hampshire, specializes in developing advanced 3D digital ear scanning technology. The company offers the FDA-cleared AURA system, which captures comprehensive data from the outer ear to deep within the ear canal, enabling designers to create personalized in-ear devices with superior comfort and sound quality. This includes custom in-ear headphones, musicians' monitors, hearing aids, and noise protection solutions. Lantos' technology enhances clinical efficiency for audiologists by providing precise measurements, improving patient outcomes, and streamlining the process for faster turnaround times on custom devices.

Diesel Labs

Seed Round in 2018
Diesel Labs, founded in 2016 and based in Boston, Massachusetts, operates as a content intelligence company. It specializes in measuring audience attention across various entertainment platforms such as Twitter, YouTube, TikTok, Facebook, and Instagram. By analyzing the engagement of millions of users with content on these platforms, Diesel Labs helps media companies make informed decisions about content creation, distribution, and measurement strategies to enhance audience engagement and subscribership.

Altiostar

Venture Round in 2017
Altiostar Networks, Inc., established in 2011 and headquartered in Tewksbury, Massachusetts, specializes in designing and developing outdoor coverage and capacity solutions for the LTE market. The company offers macro iRRH radios, suitable for various outdoor environments and mountable on cell towers, masts, or building walls. Additionally, they provide small cell iRRHs, designed to maximize network capacity in high user-density urban zones and address network coverage gaps. Altiostar serves mobile network operators, aiming to enhance communication experiences while reducing technology costs. The company's innovative, experienced team focuses on disaggregated, multi-vendor, cloud-native mobile network solutions to enable efficient and cost-effective LTE network deployment and expansion.

Anova Data

Series B in 2015
Anova Data, established in 2015 and based in Westford, Massachusetts, specializes in comprehensive analytics solutions for telecommunications networks. The company offers an end-to-end analytics framework that empowers network operators to proactively manage their systems by unlocking the full potential of subscriber and network data insights. Anova's software suite covers various operational functions such as marketing, monetization, customer care, network assurance, and service orchestration, enabling operators to effectively navigate unprecedented subscriber data growth and regain control over their networks.

SpaceOAR

Series D in 2014
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Zettics

Series D in 2013
Zettics is a provider of mobile analytics and measurement applications, specializing in delivering comprehensive insights into data usage for telecommunications operators. The company offers a robust monitoring and analytics tool that enhances real-time visibility across various applications, including video and messaging. By enabling operators to better understand subscriber behavior and trends, Zettics helps them extract greater value from their customer relationships while ensuring compliance with privacy policies. Its solutions support over 60 use cases, allowing operators to monetize data with third parties, enrich customer relationship management systems, identify network abuse, analyze pricing plans, enhance advertising strategies, reduce churn, and forecast network usage growth. Overall, Zettics empowers telecommunications operators to optimize their networks and improve their service offerings, resulting in a significant return on investment.

nVision Medical

Series A in 2013
nVision Medical Corporation is a privately-held medical device company based in Saratoga, California, focused on advancing women's health innovation. Established in 2009, the company specializes in developing devices to assess and treat female infertility resulting from fallopian tube dysfunction. nVision's products are designed not only to detect conditions such as ovarian cancer and tube blockage but also to address the challenges faced in diagnosing and treating issues within the female reproductive tract. By concentrating on these critical areas, nVision aims to improve clinical outcomes and enhance the overall health of women. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation.

Sera Prognostics

Series A in 2011
Sera Prognostics, Inc. is a biotechnology company that develops diagnostic tests to predict a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy complications. Using proteomics and bioinformatics, it discovers and commercializes blood-based biomarker tests and predictive analytics to guide early, personalized interventions and reduce healthcare costs associated with pregnancy complications. Founded in 2008 and based in Salt Lake City, Utah, Sera aims to improve maternal and neonatal outcomes by providing physicians with actionable risk information during pregnancy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.